Brokerages predict that Antares Pharma Inc (NASDAQ:ATRS) will report $31.41 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Antares Pharma’s earnings. The highest sales estimate is $33.20 million and the lowest is $30.20 million. Antares Pharma posted sales of $18.82 million in the same quarter last year, which would indicate a positive year over year growth rate of 66.9%. The firm is expected to issue its next earnings report on Thursday, February 27th.
On average, analysts expect that Antares Pharma will report full-year sales of $117.54 million for the current financial year, with estimates ranging from $116.30 million to $119.60 million. For the next year, analysts expect that the business will post sales of $155.50 million, with estimates ranging from $145.80 million to $164.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The business had revenue of $34.31 million for the quarter, compared to analysts’ expectations of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%.
Shares of ATRS traded up $0.10 on Friday, reaching $4.16. The stock had a trading volume of 2,665,200 shares, compared to its average volume of 2,156,145. Antares Pharma has a twelve month low of $2.53 and a twelve month high of $4.22. The firm has a market capitalization of $662.70 million, a PE ratio of -104.00 and a beta of 0.80. The company has a quick ratio of 2.46, a current ratio of 2.95 and a debt-to-equity ratio of 1.00. The firm has a 50-day moving average of $3.49 and a 200 day moving average of $3.21.
Several institutional investors have recently made changes to their positions in the company. Monarch Partners Asset Management LLC grew its stake in shares of Antares Pharma by 51.1% during the third quarter. Monarch Partners Asset Management LLC now owns 167,820 shares of the specialty pharmaceutical company’s stock valued at $561,000 after acquiring an additional 56,770 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Antares Pharma during the third quarter valued at about $145,000. California Public Employees Retirement System grew its stake in shares of Antares Pharma by 21.3% during the third quarter. California Public Employees Retirement System now owns 255,971 shares of the specialty pharmaceutical company’s stock valued at $856,000 after acquiring an additional 44,976 shares in the last quarter. Sargent Investment Group LLC grew its stake in shares of Antares Pharma by 3.4% during the third quarter. Sargent Investment Group LLC now owns 3,324,890 shares of the specialty pharmaceutical company’s stock valued at $11,122,000 after acquiring an additional 108,315 shares in the last quarter. Finally, Cadence Capital Management LLC acquired a new stake in shares of Antares Pharma during the third quarter valued at about $102,000. Institutional investors own 38.33% of the company’s stock.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Story: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.